VRNA vs. LGND, GMTX, PCRX, IRWD, COLL, XNCR, SYRE, BLTE, MIRM, and KNSA
Should you be buying Verona Pharma stock or one of its competitors? The main competitors of Verona Pharma include Ligand Pharmaceuticals (LGND), Gemini Therapeutics (GMTX), Pacira BioSciences (PCRX), Ironwood Pharmaceuticals (IRWD), Collegium Pharmaceutical (COLL), Xencor (XNCR), Spyre Therapeutics (SYRE), Belite Bio (BLTE), Mirum Pharmaceuticals (MIRM), and Kiniksa Pharmaceuticals (KNSA). These companies are all part of the "pharmaceutical preparations" industry.
Verona Pharma (NASDAQ:VRNA) and Ligand Pharmaceuticals (NASDAQ:LGND) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, community ranking, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.
Ligand Pharmaceuticals has higher revenue and earnings than Verona Pharma. Verona Pharma is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Verona Pharma has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500. Comparatively, Ligand Pharmaceuticals has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500.
In the previous week, Verona Pharma had 4 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 7 mentions for Verona Pharma and 3 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 0.50 beat Verona Pharma's score of 0.42 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media.
Verona Pharma presently has a consensus target price of $33.60, indicating a potential upside of 124.75%. Ligand Pharmaceuticals has a consensus target price of $116.33, indicating a potential upside of 59.73%. Given Verona Pharma's higher probable upside, analysts clearly believe Verona Pharma is more favorable than Ligand Pharmaceuticals.
Ligand Pharmaceuticals has a net margin of 37.80% compared to Verona Pharma's net margin of 0.00%. Ligand Pharmaceuticals' return on equity of 11.98% beat Verona Pharma's return on equity.
Ligand Pharmaceuticals received 220 more outperform votes than Verona Pharma when rated by MarketBeat users. However, 79.90% of users gave Verona Pharma an outperform vote while only 69.92% of users gave Ligand Pharmaceuticals an outperform vote.
85.9% of Verona Pharma shares are held by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are held by institutional investors. 4.8% of Verona Pharma shares are held by company insiders. Comparatively, 10.4% of Ligand Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Ligand Pharmaceuticals beats Verona Pharma on 12 of the 17 factors compared between the two stocks.
Get Verona Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for VRNA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VRNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Verona Pharma Competitors List
Related Companies and Tools
